Alzheimer’s disease, the most common form of dementia, continues to devastate millions of lives worldwide. With no definitive cure, current treatments focus primarily on symptom management, leaving a significant gap in therapies that address the underlying causes of the disease.
In an unexpected turn, recent research has explored the use of two existing cancer drugs as potential treatments for Alzheimer’s — offering hope that answers may lie in the unlikeliest of places. Repurposing drugs is not a new concept in medicine.
When a medication already approved for one condition shows potential for treating another, it can fast-track development timelines and reduce costs. In the case of Alzheimer’s, researchers have turned their attention to dasatinib and quercetin, two drugs traditionally used in cancer treatment, for their ability to clear toxic cells in the brain and potentially halt disease progression.
More Read: Fat-Trapping Microbeads Deliver Drug-Free Weight Loss in Rats, Study Shows
Understanding Alzheimer’s Disease
To grasp why cancer drugs are even being considered as treatments, it’s essential to understand what Alzheimer’s does to the brain.
Alzheimer’s disease is characterized by:
- Amyloid plaques: Clusters of protein fragments that accumulate between brain cells.
- Tau tangles: Twisted fibers that build up inside neurons.
- Inflammation and neuronal death: As the disease progresses, brain cells lose function and die.
These pathological features disrupt communication between brain cells, impair memory, and eventually lead to complete cognitive decline. While the precise cause of Alzheimer’s is still unclear, inflammation and cellular senescence (cells that stop dividing and accumulate abnormally) are now thought to play significant roles.
The Link Between Cancer Drugs and Brain Health
At first glance, cancer and Alzheimer’s appear to be polar opposites. Cancer is characterized by uncontrolled cell growth, while Alzheimer’s involves widespread cell death. Yet both conditions share one key mechanism: cellular senescence.
What is Cellular Senescence?
Senescence is a biological process where cells permanently stop dividing but do not die. These “zombie cells” linger in the body, secreting harmful substances that can damage surrounding cells and tissues. Over time, their accumulation contributes to aging and age-related diseases — including Alzheimer’s.
Researchers now believe that clearing these senescent cells from the brain could reduce inflammation and potentially slow or even reverse neurodegeneration.
Meet the Cancer Drugs: Dasatinib and Quercetin
Dasatinib
Originally developed to treat chronic myeloid leukemia, dasatinib is a tyrosine kinase inhibitor. It targets abnormal proteins in cancer cells that drive rapid growth and survival. Interestingly, dasatinib has shown the ability to eliminate senescent cells in animal models.
Quercetin
Quercetin is a plant-based flavonoid found in foods like apples, onions, and berries. Though less potent than dasatinib, it also exhibits senolytic properties — meaning it can help clear senescent cells. It has antioxidant and anti-inflammatory effects and is often sold as a dietary supplement.
When used in combination, dasatinib and quercetin have shown synergistic effects in eliminating senescent cells, especially in brain tissues.
Landmark Studies and Clinical Trials
Animal Studies
In 2018, a study published in Nature Medicine demonstrated that a combination of dasatinib and quercetin could reduce the number of senescent cells in aged mice, leading to improved physical function and longer lifespans.
In 2020, another mouse model of Alzheimer’s revealed that treatment with the D+Q combination:
- Reduced tau pathology
- Improved memory performance
- Decreased brain inflammation
First Human Trial
The first clinical trial in humans, conducted at the Mayo Clinic, involved patients with mild cognitive impairment (MCI) — often a precursor to Alzheimer’s. Participants received the dasatinib and quercetin combo for three months. Early results showed:
- Improved biomarkers related to senescence
- Good tolerability of the drugs
- Promising cognitive improvements in some patients
However, these were pilot results, and more extensive trials are required before any firm conclusions can be drawn.
How Do These Drugs Work Against Alzheimer’s?
Dasatinib and quercetin work together to target and destroy senescent cells. Here’s a step-by-step explanation:
- Identify Senescent Cells: Both drugs are thought to recognize certain proteins expressed only in senescent cells.
- Trigger Apoptosis: The drugs initiate apoptosis (programmed cell death) in those cells, allowing the body to clear them.
- Reduce Inflammation: By removing senescent cells, the inflammatory signals they release are also reduced.
- Improve Brain Function: With reduced inflammation and cellular “clutter,” neurons function more effectively.
This mechanism may help not only in Alzheimer’s but also in Parkinson’s, osteoarthritis, and cardiovascular diseases.
Challenges and Considerations
Despite the promise, there are still significant hurdles before dasatinib and quercetin could become standard Alzheimer’s treatments.
Safety and Dosage
- Dasatinib is a powerful cancer drug with potential side effects, including immune suppression and bleeding.
- The right dosage for long-term Alzheimer’s treatment is still unknown.
- Interactions with other medications, especially in elderly patients, must be considered.
Limited Data
- Most of the current evidence comes from animal studies and small human trials.
- Large-scale, randomized, placebo-controlled studies are essential.
Long-Term Effects
- It’s unclear whether eliminating senescent cells will have lasting cognitive benefits or unintended consequences.
- Will patients need continuous treatment? Will the brain regenerate properly after senescent cells are removed?
Ethical and Regulatory Implications
Using cancer drugs to treat dementia involves both medical and ethical considerations:
- Access and Affordability: Dasatinib is expensive. Would insurance cover its off-label use?
- Regulatory Hurdles: The FDA has yet to approve these drugs for Alzheimer’s. Drug repurposing can be slow despite promising results.
- Informed Consent: Alzheimer’s patients may not always be in a position to consent to experimental treatments.
The Future: What’s Next?
The field of senolytics — drugs that remove senescent cells — is rapidly evolving. Many biotech companies are racing to develop safer and more effective senolytic therapies specifically tailored to neurodegenerative diseases.
Ongoing Clinical Trials
Several Phase 2 clinical trials are underway, investigating not just D+Q but also other senolytic combinations. If successful, they may open the door to multi-drug regimens that can target Alzheimer’s more comprehensively.
Complementary Approaches
- Future treatments may combine senolytics with:
- Immunotherapies targeting amyloid and tau proteins
- Lifestyle interventions like diet, exercise, and sleep hygiene
- Brain stimulation and neuroplasticity therapies
Frequently Asked Question
What are dasatinib and quercetin, and how are they used?
Dasatinib is a chemotherapy drug for leukemia, while quercetin is a plant-derived supplement with antioxidant properties. Together, they form a senolytic treatment that may help remove toxic, senescent cells from the brain.
How do these drugs work against Alzheimer’s?
They target and eliminate senescent cells in the brain, reducing inflammation and potentially improving neuronal function and cognitive symptoms.
Are these drugs currently approved for Alzheimer’s?
No. They are approved for other uses (like cancer), but their use for Alzheimer’s is still experimental and under clinical investigation.
What are the potential risks or side effects?
Dasatinib can cause side effects such as fatigue, bleeding, and immune suppression. Quercetin is generally safe but may cause mild headaches or upset stomach.
Are any Alzheimer’s patients currently taking these drugs?
Yes, but only within clinical trials or under careful medical supervision in experimental settings.
Can I take quercetin supplements to prevent Alzheimer’s?
There’s no solid evidence that over-the-counter quercetin prevents Alzheimer’s. Self-treatment without medical supervision is not recommended.
When might these drugs be available as an Alzheimer’s treatment?
If ongoing clinical trials show strong results, it may take several more years before they receive regulatory approval for Alzheimer’s disease.
Conclusion
While it’s too soon to declare victory, the idea that two cancer drugs — dasatinib and quercetin — could play a role in defeating Alzheimer’s is both thrilling and scientifically plausible. By targeting the overlooked mechanism of cellular senescence, researchers have opened a new front in the battle against this devastating disease. As with all medical breakthroughs, time, patience, and rigorous testing will determine if this approach becomes a pillar of Alzheimer’s treatment. For now, we watch with hope as science dares to think outside the box — or, in this case, the pill bottle.
